Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry DiseaseBusiness Wire • 02/07/22
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to SangamoBusiness Wire • 01/06/22
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual ConferenceBusiness Wire • 01/04/22
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene TherapyBusiness Wire • 12/12/21
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell DiseaseBusiness Wire • 12/12/21
Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a BetZacks Investment Research • 11/08/21
Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/21
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial ResultsBusiness Wire • 11/04/21
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry DiseaseBusiness Wire • 11/04/21
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and WebcastBusiness Wire • 10/28/21
Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to DeclineZacks Investment Research • 10/27/21
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare ConferenceBusiness Wire • 08/09/21
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/05/21
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial ResultsBusiness Wire • 08/05/21
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and WebcastBusiness Wire • 07/29/21
Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/21
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the CenturyInvestorPlace • 07/01/21